Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | GBA1 | P04062 | 3/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21314455 | 1.00 | EEF2K (0.42) | EEF2KKMT2ASMN1; SMN2CES2CES1 | |
| SCHEMBL14698312 | 0.88 | KMT2A (0.38) | EEF2KKMT2ASMN1; SMN2CES2CES1 | |
| Hydrochloric Acid SCHEMBL19949271 | 0.86 | KMT2A (0.37) | EEF2KKMT2ASMN1; SMN2CES2CES1 | |
| Hydrochloric Acid SCHEMBL19949272 | 0.86 | KMT2A (0.37) | EEF2KKMT2ASMN1; SMN2CES2CES1 | |
| SCHEMBL5720869 | 0.82 | KMT2A (0.55) | KMT2ASMN1; SMN2CES2CES1GBA1 | |
| SCHEMBL4011437 | 0.82 | KMT2A (0.55) | KMT2ASMN1; SMN2CES2CES1GBA1 | |
| SCHEMBL30661805 | 0.82 | KMT2A (0.55) | KMT2ASMN1; SMN2CES2CES1GBA1 | |
| SCHEMBL3511663 | 0.82 | KMT2A (0.55) | KMT2ASMN1; SMN2CES2CES1GBA1 | |
| SCHEMBL22088585 | 0.81 | CES2 (0.45) | EEF2KCES2CES1FFAR1CTSA | |
| Hydrochloric Acid SCHEMBL4014614 | 0.80 | KMT2A (0.54) | KMT2ASMN1; SMN2CES2CES1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538526-B1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| CN-110167934-B | Cyclobutane-and azetidine-containing monocyclic and spiro compounds as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3538526-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
| US-20180237441-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| CN-108349984-A | The derivative of 1- Phenylpyrrolidine -2- ketone as PERK inhibitor | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2018-07-31 | — | — | CN | disclosed |
| US-20110306593-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-20110218341-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218341-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-7960310-B2 | Method of combating and controlling insects | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-14 | — | — | US | disclosed |
| US-7960310-B2 | Method of combating and controlling insects | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-14 | — | — | US | disclosed |
| EP-1919886-B1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010056722-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20080300285-A1 | Chemical Compounds | SYNGENTA CROP PROTECTION, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300285-A1 | Chemical Compounds | SYNGENTA CROP PROTECTION, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2007020377-A2 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | EEF2K 3392/4885KMT2A 3659/4885SMN1; SMN2 2576/4885 |
| US-20080300285-A1 | Chemical Compounds | CHRM5, OR10J3, CHRM3 | EEF2K 4828/4885KMT2A 2973/4885SMN1; SMN2 1754/4885 |
| US-20110306593-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | EEF2K 1176/4885KMT2A 3486/4885SMN1; SMN2 536/4885 |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | EEF2K 3375/4885KMT2A 3761/4885SMN1; SMN2 2721/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | EEF2K 3398/4885KMT2A 3748/4885SMN1; SMN2 2790/4885 |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | EEF2K 3662/4885KMT2A 3517/4885SMN1; SMN2 2636/4885 |
| US-20180237441-A1 | Chemical Compounds | PSEN1, IRS1, CPT1A | EEF2K 255/4885KMT2A 4383/4885SMN1; SMN2 51/4885 |
| US-20110218341-A1 | CHEMICAL COMPOUNDS | OR10J3, NR0B1, NR0B2 | EEF2K 4822/4885KMT2A 2793/4885SMN1; SMN2 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.